Celltrion Sees Little Threat From ‘Overheated’ Biosimilar Competition
Presenting Q2 Results, Korean Giant Questions Ability Of Smaller Players To Survive
Executive Summary
Celltrion shrugged off challenges from smaller biosimilars players, calling out “overheated competition from new entrants” as it delivered its results and strategic developments for the second quarter of 2024, including pipeline updates paving the way for trials for its proposed Keytruda and Cosentyx biosimilars.